


History



Mitsubishi Tanabe Pharma's History since Its Establishment

■ New product launches

2007

- October** ▶ Establishment of Mitsubishi Tanabe Pharma through the merger of Tanabe Seiyaku and Mitsubishi Pharma (President and Representative Director, Natsuki Hayama)

for Kremezin, a treatment for chronic kidney disease

2008

- April** ▶ Establishment of Tanabe Seiyaku Hanbai, a subsidiary handling generic drugs
- May** ▶ Announcement of Corporate Behavior Charter and Medium-Term Management Plan 08–10: Dynamic Synergy for 2015
- August** ▶ Choseido Pharmaceutical became a subsidiary, start of comprehensive, equity-based alliance centered on the generic drugs business
- October** ▶ Merger of MP-Technopharma and Tanabe Seiyaku Yamaguchi, establishment of Mitsubishi Tanabe Pharma Factory

2010

- September** ▶ Acquisition by Novartis, of Switzerland, of approval in the U.S. for Gilenya, a treatment agent for multiple sclerosis

2009

- June** ▶ Michihiro Tsuchiya became president and representative director
- October** ▶ Head Office relocated to Kitahama, Chuo-ku, Osaka
- November** ▶ Acquisition of domestic sales rights from Kureha

2011

- March** ▶ Acquisition by Novartis, of Switzerland, of approval in Europe for Gilenya, a treatment agent for multiple sclerosis
- April** ▶ Transfer of domestic sales of Kremezin, a treatment for chronic kidney disease, from Daiichi Sankyo to the Company
- August** ■ Launch of Lexapro, an anti-depressant, and start of joint sales with Mochida Pharmaceutical
- September** ■ Launch of Simponi, a treatment agent for RA, and start of joint sales with Janssen Pharmaceutical K.K.
- October** ▶ Announcement of Medium-Term Management Plan 11–15: New Value Creation
- November** ■ Launch of Imusera, a treatment agent for MS
- Launch of Telavic, a treatment agent for chronic hepatitis C

2012

- March**
- ▶ Conclusion of strategic joint sales agreement with Daiichi Sankyo for Tenelia and Canaglu, treatments for type 2 diabetes mellitus
 - ▶ Receipt of Fiscal 2012 Pharmaceutical Society of Japan Award for Drug Research and Development for fingolimod hydrochloride (Imusera), a treatment agent for MS
- May**
- ▶ Relocation of Tokyo Head Office to Koamicho, Nihonbashi, Chuo-ku, Tokyo
- July**
- ▶ Transfer of fine chemical operations to API Corporation and TAISHO TECHNOS
- September**
- Launch of Tenelia, a treatment agent for type 2 diabetes mellitus
- October**
- ▶ Establishment of Japan Blood Products Organization in joint initiative with the Japanese Red Cross Society and transfer of plasma fractionation operations
 - ▶ Comprehensive consignment to Collabo-Create of distribution operations that had been handled by MP Logistics
 - ▶ Dissolution of comprehensive, equity-based alliance, centered on the generic drug business, with Choseido Pharmaceutical
 - Launch of Tetrabik, a pertussis-diphtheria-tetanus-inactivated polio combined vaccine

2013

- March**
- ▶ Acquisition by Janssen Pharmaceuticals, of the U.S., of approval for Invokana, a treatment agent for adult type 2 diabetes mellitus
- June**
- ▶ Transfer of Tanabe Europe to API Corporation
- September**
- ▶ Medicago, of Canada, a biopharmaceutical company, became a consolidated subsidiary

2014

- March**
- ▶ Receipt of Fiscal 2014 Pharmaceutical Society of Japan Award for Drug Research and Development for SGLT2 inhibitor canagliflozin (Canaglu), a new treatment agent for type 2 diabetes mellitus
- April**
- ▶ Transfer of Mitsubishi Tanabe Pharma Factory's Ashikaga Plant to CMIC HOLDINGS
- June**
- ▶ Masayuki Mitsuka became president and representative director
- September**
- Launch of Canaglu, a treatment agent for type 2 diabetes mellitus

2015

- March**
- ▶ Termination of plasma fractionation product sales agreement with Japan Blood Products Organization
- April**
- ▶ Relocation of Head Office to Doshomachi, Chuo-ku, Osaka
 - ▶ Transfer of Mitsubishi Tanabe Pharma Factory's Kashima Plant to Sawai Pharmaceutical
- May**
- ▶ Opening of Mitsubishi Tanabe Pharma Historical Museum
 - ▶ Receipt of commendation at the Fiscal 2015 National Commendation for Invention for discovery of diabetes treatment agent teneligliptin (Tenelia)
- November**
- ▶ Announcement of Medium-Term Management Plan 16–20: Open Up the Future

2016

- January**
- ▶ Establishment of Mitsubishi Tanabe Pharma Singapore in Singapore
- February**
- ▶ Establishment of Mitsubishi Tanabe Pharma America, a pharmaceutical sales company, in the U.S.
- May**
- ▶ Receipt of METI Minister's Award at the Fiscal 2016 National Commendation for Invention for discovery of diabetes treatment agent canagliflozin (Canaglu)
- November**
- ▶ Establishment of Mitsubishi Tanabe Pharma (Thailand), a pharmaceutical sales company, in Thailand

2017

- February**
- ▶ Receipt of Okochi Memorial Technology Prize at the 63rd Okochi Prize awards for fingolimod hydrochloride, a treatment agent for MS
- April**
- ▶ Establishment of Tanabe Palm Service, which will be certified as a special subsidiary
- August**
- Launch of Radicava, an ALS treatment agent, in the U.S.
- September**
- ▶ Start of operations of BIKEN Co., a vaccine production joint venture
 - Launch of Canalia (Tenelia-Canaglu combination drug), a treatment agent for type 2 diabetes mellitus
- October**
- ▶ Transfer of generic drugs business to Nipro
 - ▶ NeuroDerm, of Israel, a pharmaceutical development company, became a consolidated subsidiary
- November**
- Launch of Rupafin, a treatment agent for allergic disorders

2018

- February**
- ▶ Stelic Institute & Co., a pharmaceutical development company, became a consolidated subsidiary
- March**
- ▶ Closure of Mitsubishi Tanabe Pharma Factory's Osaka Plant
- April**
- ▶ Establishment of Mitsubishi Tanabe Pharma Canada, a pharmaceutical sales company, in Canada
- May**
- ▶ Diabetes treatment agent Canagliflozin, which has a revolutionary treatment concept, won the Technology Award Grand Prize from the Japan Chemical Industry Association (JCIA)
- July**
- ▶ Awarded 43rd Inoue Harushige Prize for research and development on edaravone as a novel treatment agent for amyotrophic lateral sclerosis (ALS)
- December**
- ▶ Establishment of Mitsubishi Tanabe Pharma Malaysia, a pharmaceutical sales company, in Malaysia

2019

- January**
- ▶ Establishment of Mitsubishi Tanabe Pharma Provision through a change to the name and purpose of Tanabe Total Service
- April**
- ▶ Transfer of Tanabe Seiyaku Yoshiki Factory to Nipro Pharma